323P Five-year efficacy and safety in a randomized phase III trial investigating duration of adjuvant oxaliplatin-based therapy (3- vs. 6-months) for patients with high-risk stage II colon cancer: ACHIEVE-2 trial.

Authors :: Makiyama, A.
Yamazaki, K.
Shiozawa, M.
Manaka, D.
Kotaka, M.
Sakamoto, Y.
Shiomi, A.
Munemoto, Y.
Rikiyama, T.
Fukunaga, M.
Takashi, U.
Shitara, K.
Shinkai, H.
Tanida, N.
Oki, E.
Misumi, T.
Sunami, E.
Ohtsu, A.
Maehara, Y.
Yoshino, T.
Source :: Annals of Oncology. 2022 Supplement 7, Vol. 33, pS686-S686. 1p.
Publication Year :: 2022

Full Text Access

Tools